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Abstract
A simple and sensitive method to quantitatively measure the cytolytic effect of tumor-specific T killer cells is highly desirable
for basic and clinical studies. Chromium (
51Cr) release assay has been the ‘‘gold standard’’ for quantifying cytolytic activities
of cytotoxic T lymphocytes (CTLs) against target cells and this method is still being used in many laboratories. However, a
major drawback of this method is the use of radioactive materials, which is inconvenient to handle because of
environmental safety concerns and expensive due to the short half-life of the isotope. Consequently, several nonradioactive
methods have been reported recently. Here we report a new method that we recently developed for quantifying antigen-
specific cytolytic activity of CTLs. This method fully exploits the high sensitivity and the relative simplicity of luciferase
quantitative assay. We initially expected the released luciferase in the supernatant to be the adequate source for monitoring
cell death. However, to our total surprise, incubation of these killer T cells with the tumor cell targets did not result in
significant release of luciferase in the culture medium. Instead, we found that the remaining luciferase inside the cells could
accurately reflect the overall cell viability.
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Introduction
Cytotoxic T lymphocytes (CTLs) play an important role in the
host’s defense against intracellular pathogens and malignant cells
[1]. A simple and sensitive method to measure their activity would
greatly benefit basic and clinical studies. For a long time,
chromium (
51Cr) release assay has remained as the ‘‘gold
standard’’ for quantifying cytolytic activities of CTLs against
target cells and this method is still being used in many laboratories
around the world [2,3]. However, a major drawback of the
51Cr
release assay is the use of radioactive materials, which are
inconvenient to handle because of environmental safety concerns
and expensive due to the short half-life of the isotope.
Consequently, several nonradioactive methods have been reported
recently. One such method measures the release of endogenous
enzymes (e.g., lactate dehydrogenase) in the supernatant during
the CTL-mediated cytolysis of target cells [4]. However, dead
effector cells could also release the same enzyme, which may
compromise the accuracy of quantification by this method.
Another method, reported recently, uses fluorescent dye to label
the target cells [5] or transduces target cells with the gene encoding
the green fluorescent protein [6,7]. However, disadvantages of
these methods include high spontaneous release of the fluorescent
dye, low intensity of the fluorescence signal, and the requirement
of expensive and sophisticated equipments such as flow cytometry.
Here we report a new method that we recently developed
for quantifying antigen-specific cytolytic activity of CTLs. This
method fully exploits the high sensitivity and the relative
simplicity of luciferase quantitative assay, while avoiding the
disadvantages of radioactive methods. We initially transduced
target cells with a piggyBac transposon/transposase vector con-
taining a fusion gene of GFP and luciferase, by which stable cell
lines containing the fusion gene could be conveniently selected
and established. We then examined the feasibility of using
quantitative assays of luciferase activity to determine the cytolytic
effect of modified T cells that can specifically recognize these
tumor cells. We initially expected the released luciferase in the
supernatant to be the adequate source for monitoring cell death.
However, to our total surprise, incubation of these killer T cells
with the tumor cell targets did not result in any detectable
luciferase activity in the culture medium. Instead, we found that
the remaining luciferase inside the cells could accurately reflect
the overall cell viability.
Materials and Methods
Plasmid construction
Construction of pIR-Her2 plasmid. The HER2 sequence was
cut out from a HER2 WT plasmid, which was kindly provided by
Dr. Mien-Chie Hung (M.D. Anderson Cancer Center). The entire
gene was cleaved out using HindIII and blunt-end ligated into the
piggyBac-containing plasmid pIR-eGFP [8], which had been
digested with XhoI and NotI. This replaced the GFP gene in pIR-
eGFP with HER2. The new plasmid is designated pIR-Her2.
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fusion gene, eGFP-luc, was cut out from the SFP-eGFP-luc
plasmid with XbaI and MluI. Then eGFP-luc was blunt-end
ligated into pIR-eFGFP which had been digested with BamHI.
This replaced the GFP gene in pIR-eGFP with the eGFP-luc
fusion gene. The new plasmid was designated pIR-eGFP-luc.
Establishment of a stable tumor cell line expressing both
HER2 and eGFP-luc
4T1 cells are a 6-thioguanine-resistant cell line derived
originally from a BALB/c spontaneous mammary carcinoma [9]
and was kindly provided by Dr. Fred Miller (Michigan Cancer
Foundation, Detroit, MI, USA). Initially 4T-1 cells were co-
transfected with three plasmids: pIR-Her2, pIR-eGFP-luc and
pCMV-piggyBac. pCMV-piggyBac contains the piggyBac trans-
posase that will recognize the ITR sequence in the other two
plasmids and enforce integration [10]. After transfection, the cells
were selected with puromycin at a concentration of 2 mg/ml. Then
GFP-positive cells were sorted to more than 90% purity with BD
FACS AriaII (BD Biosciences, San Jose, California). The sorted
GFP positive cells were then seeded as single cells in 96-well plate
by limiting dilution and screened for colonies expressing HER2 by
staining them with PE conjugated -anti-human HER2 antibody
(BioLegend, San Diego, CA).
Transduction of murine splenocytes with retroviral vector
containing chimeric TCR
The construction of the retroviral vector (SFG-Her2-CD28-
Zeta) containing chimeric TCR that specifically recognizes HER2
has been described [11]. To produce the retroviral vector stock,
SFG-Her2-CD28-Zeta were co-transfected with the packaging
plasmid, pCL-ECO, by using lipofectamine 2000 (Invitrogen,
Carlsbad, CA). Supernatants containing the retrovirus were
collected 48 and 72 h later and were used to transduce freshly
harvested splenocytes from Balb/C mice. Briefly, splenocytes were
harvested from Balb/C mice and cultured with RPMI 1640
medium supplemented with 25 mM HEPES, 200 nM L-gluta-
mine, 10% FBS, 1% MEM non-essential amino acids, 1 mM
sodium pyruvate, 50 mM b-mercaptoethanol, 100 mg/ml strepto-
mycin and 100 U/ml penicillin. Single-cell suspensions (26106/
ml) were activated with Concanavalin A (2 mg/ml; Sigma, St.
Louis, MO) for 24 h. The stimulated cells were transduced with
Her2-CD28-Zeta retrovirus supernatant in the RetroNectin
(Takara Bio. Inc., Shiga, Japan) precoated non–tissue culture 24-
well plate. The retroviral vector routinely transduces the cells at
approximately 50% efficiency. The transduced splenocytes were
then cultured for 48 hours in fresh medium supplemented with
mIL-2 (10ng/ml) to allow the cells to recover. They were then
used directly for T cell mediated cytotoxicity assay.
Quantification of cell viability and luciferase activity
The cell viability was determined by Trypan blue exclusion
assay after counting viable cells with a hemocytometer. All
luciferase assays were performed with Bright-Glo
TM Luciferase
Assay System (Promega, Madison, WI), and were conducted
essentially according to the manufacturer’s protocol. For measur-
ing cell-associated luciferase activity, culturing medium was
removed. The mixture of 50 ml of the prepared luciferase reagent
and 50 ml PBS was added to each well of the 96-well plates and the
plates were shaken gently for 5 minutes for the cells to be
completely lysed. The lysed mixture was then transferred into the
provided plate for luminescence measurements with a luminom-
eter. For measuring luciferase activity in the medium, 50 ml
medium was directly mixed with 50 ml of the prepared luciferase
reagent. Luminescence measurements were performed with a
SpectraMaxH multi-mode microplate reader (Molecular Devices,
Sunnyvale, CA).
Statistical analysis
All data were expressed as mean 6 standard deviation.
Correlation coefficient analysis was performed with Pearson’s
product-moment coefficient method.
Results
Establishment of stable tumor cell lines that express
firefly luciferase
To facilitate the establishment of the stable cell lines, we
employed the piggyBac transposon/transposase vector system.
This system requires only the inverted terminal repeats (ITRs) to
flank a transgene and transient expression of the transposase
enzyme to catalyze the gene insertion into the chromosome for
stable gene expression [12]. This vector system has also been
shown to be able to insert multiple genes simultaneously [10]. For
this study, we constructed two ITR containing vectors. The first
one is pIR-gfp-luc, which contains a fusion gene of GFP and firefly
luciferase. We also constructed a transposon-based vector that
contains the HER2 gene flanked by ITR (pIR-Her2). The gene
product, human epidermal growth factor receptor 2 (HER2),
serves as a tumor antigenic target for T cell recognition and killing.
These two plasmids, together with a plasmid containing transposase
gene (pCMV-piggyBac) were co-transfected into a murine
mammary tumor cell line, 4T1, which is a well-established
syngeneic murine tumor cell line that can naturally metastasize to
many organ tissues [9]. Cells were initially selected for stable GFP
expression and cloned. Individual clones were then screened for
HER2 expression by flow cytometry. The majority of the GFP-
positive cell clones were found to also be positive for HER2
expression. One of the clones that expresses both GFP and HER2,
designated 4T1-Her2, was chosen for the subsequent studies.
To determine luciferase activity from the established cell line,
we seeded 4T1-Her2 cells in triplicate into 96-well plates at
different numbers, starting from ten thousand cells per well,
gradually decreasing to 50 cells per well. Cells were lysed two
hours after seeding for quantification of luciferase activity. The
results showed that there was good correlation between the level of
luciferase activity and the number of cells seeded (Fig. 1A).
Moreover, the data confirm that the luciferase assay is indeed
extremely sensitive. A luciferase activity of more than 3,000 units
was detected from a mere 50 cells against a barely detectable
background (Fig. 1B).
High correlation coefficiency between target cell
numbers and luciferase activity
To be a sensitive and reliable quantification method, a high
correlation coefficiency between the sample quantity and the
readout is crucial. Thus, we calculated the coefficiency from an
experiment in that different numbers of cells seeded in 96-well
plates were measured for luciferase activity. The cell numbers were
converted into percentage by dividing them with the maximal
number of cells used in this experiment, as was the luciferase
activity from each group by dividing the reading with the reading
from the maximal cell number group. Then the data was plotted.
Pearson analysis showed that there is an extremely good
correlation between the cell numbers and the level of luciferase
activity (R=0.99, Fig. 2), indicating that this detection method
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numbers.
Luciferase does not leak to the supernatant even at the
peak of CTL-mediated cytolysis
One of the main drawbacks with the fluorescent dye labeling
approach is the non-specific release of the labeling agent, which
detrimentally affects the detection specificity. To examine the level
of natural release of luciferase from the established cell line, we
seeded 10,000 4T1-Her2 cells into a 96-well plate. The
supernatants were collected at different times for quantification
of luciferase activity. The results show that the non-specific release
of luciferase in the supernatant was barely detectable even in wells
where the cell-associated luciferase activity was detected at an
extremely high level (over 400,000 units, Fig. 3), indicating that
non-specific release is not an issue with this detection method.
Due to the extremely low non-specific release of luciferase in the
supernatant, we considered that any luciferase that was released
during CTL-mediated cytolysis would be detectable and thus
would represent an extremely sensitive quantification method. For
generating tumor-specific CTLs, we adopted a previous reported
method in which a chimeric T cell receptor (TCR) was engrafted
into naı ¨ve T cells to convert them into tumor-specific killer cells
[11]. In this method, a single chain antibody specific to HER2 was
fused to the external portion of the zeta chain of the TCR
Figure 2. Pearson’s correlation coefficient analysis. 4T1-Her2
cells were seeded in 96 well plates at increasing numbers and the
luciferase level was determined after 2 hours. Both cell number and
luciferase quantity were converted into percentage by dividing the
individual figure with the maximal cell number seeded (100,000) or the
luciferase reading from the well with the maximal cell number. The
correlation coefficient (R) is indicated in the figure.
doi:10.1371/journal.pone.0011867.g002
Figure 1. Quantification of luciferase expression from serially diluted 4T1-Her2 cells. A. Cells were seeded at a large range of density
(from 10,000 to 50 per well) and were assayed for luciferase expression 2 h later. B. The assay was focused on the low cell number wells. The numbers
above each bar indicate the actual luciferase units detected.
doi:10.1371/journal.pone.0011867.g001
Figure 3. Low natural release of luciferase from 4T1-Her2 cells.
Initially 10,000 4T1-Her2 cells were seeded. The supernatants were
collected at the indicated times for measurement of luciferase.
doi:10.1371/journal.pone.0011867.g003
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recognize tumor cells expressing HER2 with pre-defined specific-
ity and in a non-MHC restricted manner. We mixed the chimeric
TCR-engrafted (cTCR) splenocytes with 4T1-Her2 cells at a 10:1
ratio. Luciferase activity was determined from both supernatant
and cell fractions. As the incubation progressed, cell-associated
luciferase activity decreased steadily. However, the luciferase
activity in the supernatant remained at a very low level even at
72 h after the cell mixture was set up (Fig. 4A), a time when severe
cytopathic effect was clearly visible and the entire 4T1-Her2
monolayer was almost completely destroyed (Fig. 4C). These
results indicate that during the cytolysis process, luciferase does not
readily release to the outside and thus the supernatant is not the
ideal source for monitoring cell viability based on luciferase assay.
Quantification of decrease in cell-associated luciferase
represents a reliable way of deducing cytolytic activity of
killer T cells
The results in Fig. 4A show that, despite the absence of
luciferase activity in the supernatant, the cell-associated luciferase
activity was proportionally reduced during the T cell-mediated
killing of 4T1-Her2 cells. Thus, we did another experiment to
thoroughly monitor the luciferase activity inside the cells during
the cytolysis of 4T1-Her2 cells by cTCR-transduced splenocytes.
We mixed the effector cells with the target cells at different ratios
and measured the luciferase activity from the cell mixture at time
points from 24 to 72 h. We did not choose a shorter time point for
this assay as the complete turn-over of luciferase, which has a half-
life of 3 h when inside cells, will take approximately 12–15 h.
Mock-engrafted splenocytes were used as a control to confirm the
tumor-killing specificity of cTCR-transduced splenocytes. While
the mock-treated splenocytes only marginally reduced the cell-
associated luciferase activity (by approximately two-fold, Fig. 5A),
incubation with cTCR-transduced splenocytes resulted in a
dramatic reduction of luciferase activity in the target cells
(Fig. 5B). When the effector cells were mixed with the target cells
at a 10:1 ratio, there was a 15-fold reduction of luciferase activity
as compared with the control. When the ratio was increased to
20:1, the luciferase activity was reduced by more than 100 fold, to
a barely detectable level (Fig. 5C). Together these results show that
cTCR T cells can efficiently and specifically lyse these tumor
target cells and that detection of cell associated luciferase activity
can be used to quantitatively monitor the lytic activity of these
engrafted T killer cells.
Discussion
Despite the proven reliability and sensitivity of the
51Cr release
assay in measuring the cytolytic activities of CTLs, concerns
related to handling radioactive materials have led to efforts to
develop non-radioactive methods. Among all the recently reported
new methods, fluorescence-based assays are the most promising.
However, these methods also share one of the drawbacks
associated with the old method; nonspecific release of the
fluorescent labeling agent. This is particularly problematic in
experiments where prolonged incubation of the effector and target
cells is required. In this study, we show that firefly luciferase, once
transduced into target cells, can serve as an attractive marker for
measuring T cell cytotoxicity. This method has several unique
features. First, luciferase has a relatively short half-life, estimated to
be around 3 h after its synthesis inside the cells [13]. Thus, its
quantitative fluctuation can accurately reflect the cell viability.
Second, unlike other methods, its non-specific release is extremely
low. This method is also highly sensitive, and recently developed
detection kits (e.g., the Bright-Glo
TM Luciferase Assay System)
with a luminescence (signal) half-life around 30 min, have further
increased the detection sensitivity. Finally, this assay is easy to
perform and does not require expensive and sophisticated
equipment.
I n i t i a l l yw es e tu pt h ee x p e r i m e n tt om o n i t o rt h el u c i f e r a s ea c t i v i t y
in the supernatant, as in other methods. Surprisingly, however,
Figure 4. Luciferase was undetectable in the supernatant during T cell-mediated 4T1-Her2 cytolysis. A. Cell-associated and supernatant
luciferase activity during cTCR-splenocyte mediated cytolysis of 4T1-Her2 cells. cTCR-splenocytes were added to 4T1-Her2 cells at a ratio of 10:1.
Supernatants and cells were harvested at the indicated time for quantification of luciferase activity. B. 4T1-Her2 monolayer without cTCR-transduced
splenocytes. C. Seventy-two h after cTCR-tranduced splenocytes were added to 4T1-Her2 monolayer.
doi:10.1371/journal.pone.0011867.g004
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cytopathic effect on target cells was clearly visible under the
microscope. One explanation for this apparent discrepancy is
probably due to the ultra short half-life of luciferase in the
supernatant. It has been reported that half-life of firefly luciferase
becomes even shorter (estimated to be 20–30 min) once it is released
to the outside environment of cell [13]. As such, the released
luciferase might have quickly gotten degraded. Another possibility is
that, due to its relatively large mass (as compared with
51Cr or
fluorochrome), it may not freely leak into the supernatant even
though plenty of pores are punched on the target cell membranes by
the perforins released from the effector cells. It has been reported that
the size of the pores punctured by perforins are relatively small
(around 16 nM in diameter), which may not allow protein molecules
to freely pass through [14]. Regardless, our data show that
measurement of cell-associated luciferase activity can be used to
quantitate the cytolytic activity during T killer cellmediated oncolysis.
Although we did not directly compare our method with the
‘‘gold standard’’
51Cr release assay, we believe that the sensitivity
of these two methods is comparable.
51Cr release assay has been
frequently used by many laboratories to measure the killing
activity of T cells engrafted with chimeric TCRs [15,16]. The
detection sensitivity seems to be similar to the method described in
this report when the amount of target cells and the E:T ratios have
been taken into consideration. The fact that luciferase from as little
as 50 cells could be readily detected by our assay supports this
assumption. A related issue is if this method is applicable to
measure cytolytic activities from CTLs that are endogenously
generated during natural antigen encounter or vaccination.
Considering that our method has similar detection sensitivity as
the widely used traditional
51Cr release assay, we feel confident
that this method can be adapted for that purpose.
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Figure 5. Reduction in cell-associated luciferase activity closely reflects the killing activity of T killer cells against tumor targets.
Mock-transduced (A) or cTCR-transduced (B) splenocytes were added to 4T1-Her2 cells at the indicated ratio. Cells were harvested 72 later for
quantification of luciferase activity. C. Using the formula: % specific luc reduction=(% luc reduction from engrafted T-cell)/(% luc reduction from
control T-cell)6100, the data from A and B were converted into percentage of specific luciferase release and plotted.
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